SG170778A1 - Antitumoral compounds - Google Patents

Antitumoral compounds

Info

Publication number
SG170778A1
SG170778A1 SG201102163-1A SG2011021631A SG170778A1 SG 170778 A1 SG170778 A1 SG 170778A1 SG 2011021631 A SG2011021631 A SG 2011021631A SG 170778 A1 SG170778 A1 SG 170778A1
Authority
SG
Singapore
Prior art keywords
antitumoral compounds
antitumoral
compounds
cancer
compound
Prior art date
Application number
SG201102163-1A
Other languages
English (en)
Inventor
Alberto Rodriguez Vicente
Maria Garranzo Garcia-Ibarrola
Carmen Murcia Perez
Francisco Sanchez Sancho
Maria Del Carmen Cuevas Marchante
Cristina Mateo Urbano
Isabel Digon Juarez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of SG170778A1 publication Critical patent/SG170778A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
SG201102163-1A 2007-12-20 2008-12-19 Antitumoral compounds SG170778A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20

Publications (1)

Publication Number Publication Date
SG170778A1 true SG170778A1 (en) 2011-05-30

Family

ID=40580474

Family Applications (2)

Application Number Title Priority Date Filing Date
SG201102163-1A SG170778A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds
SG201102164-9A SG170779A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG201102164-9A SG170779A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Country Status (27)

Country Link
US (4) US8710264B2 (ja)
EP (3) EP2231590B9 (ja)
JP (3) JP5529038B2 (ja)
KR (3) KR101579553B1 (ja)
CN (4) CN102190643B (ja)
AT (1) ATE549313T1 (ja)
AU (2) AU2008341671B2 (ja)
BR (2) BRPI0821116B8 (ja)
CA (2) CA2710087C (ja)
CY (1) CY1117245T1 (ja)
DK (2) DK2231633T3 (ja)
ES (3) ES2384420T3 (ja)
HK (3) HK1147998A1 (ja)
HR (2) HRP20120464T1 (ja)
IL (3) IL206397A (ja)
MX (2) MX2010006795A (ja)
MY (3) MY155342A (ja)
NZ (3) NZ597526A (ja)
PL (2) PL2231590T3 (ja)
PT (2) PT2231633E (ja)
RS (2) RS53140B (ja)
RU (3) RU2489429C2 (ja)
SG (2) SG170778A1 (ja)
SI (2) SI2231633T1 (ja)
UA (3) UA119963C2 (ja)
WO (2) WO2009080761A1 (ja)
ZA (3) ZA201004018B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119963C2 (uk) 2007-12-20 2019-09-10 Фарма Мар, С.А. Протипухлинні сполуки
EP2800559B1 (en) * 2012-01-05 2018-09-05 Kao Corporation Agent for reduction of sensory irritation
CA2907832A1 (en) 2013-04-16 2014-10-23 Actelion Pharmaceuticals Ltd Antibacterial biaromatic derivatives
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) * 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) * 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
EP0564561A4 (en) * 1990-12-28 1994-08-10 Georgia Tech Res Inst Peptides ketoamides, ketoacids, and ketoesters
JPH0539283A (ja) * 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) * 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
WO2000015634A2 (en) 1998-09-11 2000-03-23 Warner-Lambert Company Hiv protease inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
JP2004505890A (ja) * 2000-04-04 2004-02-26 ノバルティス　アクチエンゲゼルシャフト 抗新生物剤に耐性の細胞を処置する方法
CA2632078C (en) * 2002-03-04 2012-08-14 Sloan-Kettering Institute For Cancer Research Methods of inducing terminal differentiation
AU2004263287B2 (en) * 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
EP2032551B9 (en) 2006-06-16 2012-02-29 Pharma Mar, S.A. Antitumoral dihydropyran-2-one compounds
UA119963C2 (uk) 2007-12-20 2019-09-10 Фарма Мар, С.А. Протипухлинні сполуки

Also Published As

Publication number Publication date
JP2014133752A (ja) 2014-07-24
BRPI0821114B1 (pt) 2021-09-08
BRPI0821116B8 (pt) 2021-05-25
CN101903337B (zh) 2013-12-18
WO2009080761A1 (en) 2009-07-02
SI2231633T1 (sl) 2014-02-28
CY1117245T1 (el) 2017-04-05
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
JP2011506578A (ja) 2011-03-03
NZ586013A (en) 2012-02-24
EP2597091A1 (en) 2013-05-29
NZ597526A (en) 2012-06-29
PL2231633T3 (pl) 2014-03-31
CA2710087A1 (en) 2009-07-02
DK2231633T3 (da) 2014-01-20
HRP20140015T1 (hr) 2014-02-14
KR20100100979A (ko) 2010-09-15
HRP20120464T1 (hr) 2012-07-31
US20120041063A2 (en) 2012-02-16
PT2231590E (pt) 2012-06-25
BRPI0821114B8 (pt) 2021-11-09
MY155342A (en) 2015-10-15
KR101639772B1 (ko) 2016-07-15
EP2231590B1 (en) 2012-03-14
MY164533A (en) 2017-12-29
RU2528393C9 (ru) 2015-01-10
SI2231590T1 (sl) 2012-10-30
BRPI0821114A2 (pt) 2015-06-16
RU2010130180A (ru) 2012-01-27
KR20100125226A (ko) 2010-11-30
JP5727228B2 (ja) 2015-06-03
ES2384420T3 (es) 2012-07-04
IL206397A0 (en) 2010-12-30
HK1180678A1 (zh) 2013-10-25
JP5860088B2 (ja) 2016-02-16
CN101903367A (zh) 2010-12-01
MX2010006795A (es) 2010-10-26
EP2597091B1 (en) 2016-04-20
MY148651A (en) 2013-05-15
RU2010130253A (ru) 2012-01-27
CA2710087C (en) 2015-06-02
CN102190643B (zh) 2015-02-25
CN101903367B (zh) 2015-08-05
CN102174058A (zh) 2011-09-07
RU2013112003A (ru) 2014-08-20
AU2008341671B2 (en) 2012-07-26
CA2715203C (en) 2015-09-08
IL206397A (en) 2014-01-30
PL2231590T3 (pl) 2012-09-28
HK1147990A1 (en) 2011-08-26
ATE549313T1 (de) 2012-03-15
US8710264B2 (en) 2014-04-29
CA2715203A1 (en) 2009-07-02
RS52343B (en) 2012-12-31
KR101541436B1 (ko) 2015-08-03
EP2231633B1 (en) 2013-10-30
US20110034549A1 (en) 2011-02-10
RS53140B (en) 2014-06-30
EP2231590A1 (en) 2010-09-29
BRPI0821116A2 (pt) 2015-08-11
MX2010006796A (es) 2010-10-26
JP5529038B2 (ja) 2014-06-25
US20150342972A1 (en) 2015-12-03
HK1147998A1 (en) 2011-08-26
AU2008341670A1 (en) 2009-07-02
US9750759B2 (en) 2017-09-05
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
DK2231590T3 (da) 2012-07-09
US20150344454A1 (en) 2015-12-03
ES2442140T3 (es) 2014-02-25
IL229594A (en) 2016-02-29
BRPI0821116B1 (pt) 2020-02-18
ES2578606T3 (es) 2016-07-28
US9187445B2 (en) 2015-11-17
UA104281C2 (ru) 2014-01-27
AU2008341671A1 (en) 2009-07-02
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
UA119963C2 (uk) 2019-09-10
SG170779A1 (en) 2011-05-30
CN102190643A (zh) 2011-09-21
KR20150076265A (ko) 2015-07-06
IL206396A (en) 2014-05-28
EP2231590B9 (en) 2012-08-15
RU2493147C2 (ru) 2013-09-20
IL206396A0 (en) 2010-12-30
US9827257B2 (en) 2017-11-28
JP2011506575A (ja) 2011-03-03
ZA201004018B (en) 2011-12-28
CN101903337A (zh) 2010-12-01
ZA201004017B (en) 2011-12-28
EP2231633A1 (en) 2010-09-29
AU2008341670B2 (en) 2012-04-19
IL229594A0 (en) 2014-01-30
ZA201106371B (en) 2013-05-29
RU2528393C1 (ru) 2014-09-20
UA106967C2 (uk) 2014-11-10

Similar Documents

Publication Publication Date Title
GEP201706703B (en) Boronate ester compounds and pharmaceutical compositions thereof
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
GEP20125702B (en) Benzimidazole derivatives
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2009009290A (es) Compuestos activos en ppar.
TW200800969A (en) Compounds
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
TN2011000291A1 (en) Purine compounds
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
SG170778A1 (en) Antitumoral compounds
DE502008001158D1 (en) Benzimidazolderivate
MX2009009916A (es) Tetrahidroquinolinas sustituidas.
MY159479A (en) Herbicides
WO2010149688A3 (en) Antitumoral compounds
TW200700423A (en) Heterobicyclic acrylamides
GB0620005D0 (en) Compounds
UA91250C2 (en) 4-oxadiazolyl-piperidine compounds and use thereof